Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification
Congestive heart failure (HF) is a devastating disease leading to prolonged hospitalization, high morbidity and mortality rates, and increased costs. Well-established treatments for decompensated or unstable patients include medications and mechanical cardiac support devices. For acute HF decompensa...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.962839/full |
| _version_ | 1811271916124635136 |
|---|---|
| author | Cristiano de Oliveira Cardoso Abdelmotagaly Elgalad Ke Li Emerson C. Perin |
| author_facet | Cristiano de Oliveira Cardoso Abdelmotagaly Elgalad Ke Li Emerson C. Perin |
| author_sort | Cristiano de Oliveira Cardoso |
| collection | DOAJ |
| description | Congestive heart failure (HF) is a devastating disease leading to prolonged hospitalization, high morbidity and mortality rates, and increased costs. Well-established treatments for decompensated or unstable patients include medications and mechanical cardiac support devices. For acute HF decompensation, new devices are being developed to help relieve symptoms and recover heart and renal function in these patients. A recent device-based classification scheme, collectively classified as DRI2P2S, has been proposed to better describe these new device-based therapies based on their mechanism: dilators (increase venous capacitance), removers (direct removal of sodium and water), inotropes (increase left ventricular contractility), interstitials (accelerate removal of lymph), pushers (increase renal arterial pressure), pullers (decrease renal venous pressure), and selective (selective intrarenal drug infusion). In this review, we describe the new class of medical devices with the most current results reported in preclinical models and clinical trials. |
| first_indexed | 2024-04-12T22:30:45Z |
| format | Article |
| id | doaj.art-9e7d2333619c41d19a6aa2bf763a243d |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-12T22:30:45Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-9e7d2333619c41d19a6aa2bf763a243d2022-12-22T03:13:59ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-09-01910.3389/fcvm.2022.962839962839Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classificationCristiano de Oliveira Cardoso0Abdelmotagaly Elgalad1Ke Li2Emerson C. Perin3Center for Preclinical Surgical and Interventional Research, Texas Heart Institute, Houston, TX, United StatesCenter for Preclinical Surgical and Interventional Research, Texas Heart Institute, Houston, TX, United StatesCenter for Preclinical Surgical and Interventional Research, Texas Heart Institute, Houston, TX, United StatesCenter for Clinical Research, Texas Heart Institute, Houston, TX, United StatesCongestive heart failure (HF) is a devastating disease leading to prolonged hospitalization, high morbidity and mortality rates, and increased costs. Well-established treatments for decompensated or unstable patients include medications and mechanical cardiac support devices. For acute HF decompensation, new devices are being developed to help relieve symptoms and recover heart and renal function in these patients. A recent device-based classification scheme, collectively classified as DRI2P2S, has been proposed to better describe these new device-based therapies based on their mechanism: dilators (increase venous capacitance), removers (direct removal of sodium and water), inotropes (increase left ventricular contractility), interstitials (accelerate removal of lymph), pushers (increase renal arterial pressure), pullers (decrease renal venous pressure), and selective (selective intrarenal drug infusion). In this review, we describe the new class of medical devices with the most current results reported in preclinical models and clinical trials.https://www.frontiersin.org/articles/10.3389/fcvm.2022.962839/fullheart failureacute heart failuredevicescardiorenal syndrometreatment |
| spellingShingle | Cristiano de Oliveira Cardoso Abdelmotagaly Elgalad Ke Li Emerson C. Perin Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification Frontiers in Cardiovascular Medicine heart failure acute heart failure devices cardiorenal syndrome treatment |
| title | Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification |
| title_full | Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification |
| title_fullStr | Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification |
| title_full_unstemmed | Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification |
| title_short | Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification |
| title_sort | device based therapy for decompensated heart failure an updated review of devices in development based on the dri2p2s classification |
| topic | heart failure acute heart failure devices cardiorenal syndrome treatment |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.962839/full |
| work_keys_str_mv | AT cristianodeoliveiracardoso devicebasedtherapyfordecompensatedheartfailureanupdatedreviewofdevicesindevelopmentbasedonthedri2p2sclassification AT abdelmotagalyelgalad devicebasedtherapyfordecompensatedheartfailureanupdatedreviewofdevicesindevelopmentbasedonthedri2p2sclassification AT keli devicebasedtherapyfordecompensatedheartfailureanupdatedreviewofdevicesindevelopmentbasedonthedri2p2sclassification AT emersoncperin devicebasedtherapyfordecompensatedheartfailureanupdatedreviewofdevicesindevelopmentbasedonthedri2p2sclassification |